NCT03188484 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Abellana R, Gonzalez-Loyola F, Verdu-Rotellar JM, Bustamante A, Palà E, Clua-Espuny JL, Montaner J, Pedrote A, Del Val-Garcia JL, Ribas Segui D, Muñoz MA
Predictive model for atrial fibrillation in hypertensive diabetic patients. Eur J Clin Invest. 2021
Clua-Espuny JL, Muria-Subirats E, Ballesta-Ors J, Lorman-Carbo B, Clua-Queralt J, Palà E, Lechuga-Duran I, Gentille-Lorente D, Bustamante A, Muñoz MÁ, Montaner J; AFRICAT Research Group
Risk of Atrial Fibrillation, Ischemic Stroke and Cognitive Impairmen
García-Berrocoso T, Palà E, Consegal M, Piccardi B, Negro A, Gill N, Penalba A, Huerga Encabo H, Fernández-Cadenas I, Meisel A, Meisel C, Jickling GC, Muñoz MÁ, Clúa-Espuny JL, Pedrote A, Pagola J, Juega J, Bustamante A, Montaner J
Cardioembolic Ischemic
Muria-Subirats E, Clua-Espuny JL, Ballesta-Ors J, Lorman-Carbo B, Lechuga-Duran I, Fernández-Saez J, Pla-Farnos R, On Behalf Members Of Africat Group
Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Retrospective Co
Palà E, Bustamante A, Clúa-Espuny JL, Acosta J, Gonzalez-Loyola F, Ballesta-Ors J, Gill N, Caballero A, Pagola J, Pedrote A, Muñoz MA, Montaner J
N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Po

Stepwise High Risk Individuals Screening for Atrial Fibrillation Using Sequential Clinical-electro-biological Register: the AFRICAT Study (Atrial Fibrillation Research In CATalonia)

Details for clinical trial NCT03188484

Clinical trial NCT03188484 - References